Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

UNBELIEVABLE: Atra | History Defined

The ranks of US rabbis grow more diverse, with rising numbers of women and LGBTQ people

Rabbis and rabbinical students in the United States are more diverse than ever

The Independent UK · Feb 1

Year in review: top 10 furniture launches of 2024, as selected by Wallpaper* global design director Hugo Macdonald

The furniture launches that wowed global design director Hugo Macdonald this year

Wallpaper · Dec 26, 2024

'Showcase how neurotic you are': ATRA's furniture wants you to experiment beyond the care label

Design and architecture studio ATRA presents 'CARE INSTRUCTIONS', an exhibition of playful pieces whereby clients can 'wrap up' a sofa to meditate in an electromagnetic chair

Wallpaper · Oct 22, 2024

From analysis to the latest developments in health,
read the most diverse news in one place.

1 Penny Stock Where You Can Spend Less And Earn More

This tiny stock could soar more than 400%, according to Wall Street.

Barchart · Jun 4, 2024

Read Why Did HC Wainwright Cut Price Target On Atara Biotherapeutics

Late last week, Atara Biotherapeutics Inc (NASDAQ:ATRA) announced that Bayer AG (OTC:BAYRY) intends to terminate the exclusive worldwide licensing agreement for Atara's mesothelin-targeted allogeneic and autologous CAR-T assets, ATA3271 and ATA2271. The enrollment was paused in the Phase 1 trial of ATA2271 for mesothelioma after a patient death. The move followed a strategic review and asset-level prioritization.…

Benzinga · May 23, 2022

Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara

Atara Biotherapeutics Inc (NASDAQ:ATRA) received notification that Bayer AG's (OTC:BAYRY) intends to end the exclusive worldwide licensing agreement for mesothelin-directed CAR T-cell therapies. The collaboration included the funding and development of ATA3271, allogeneic T-cell immunotherapy, and an autologous version, ATA2271, for high mesothelin-expressing tumors. ATA3271 leverages Atara's EBV T-cell platform and is currently in IND…

Benzinga · May 20, 2022

Atara Biotherapeutics Earnings Preview

Atara Biotherapeutics (NASDAQ:ATRA) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Atara Biotherapeutics will report an earnings per share (EPS) of $-0.98.

Benzinga · May 4, 2022

Read news from The Economist, FT, and more,
with one subscription

Atara Biotherapeutics Earnings Perspective: Return On Capital Employed

Benzinga Pro data, Atara Biotherapeutics (NASDAQ:ATRA) reported Q4 sales of $7.55 million. Earnings fell to a loss of $93.35 million, resulting in a 10.26% decrease from last quarter.

Benzinga · Mar 2, 2022

Fujifilm To Buy Cell Therapy Plant From Atara For $100M

FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, will acquire a cell therapy plant from Atara Biotherapeutics Inc (NASDAQ: ATRA)

Benzinga · Jan 27, 2022

Coverage From

People

Michael Anastassiades

15 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.